Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/17623
Title: Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral leishmaniasis in hamster.
Authors: Cabrera González, Marco Antonio
Gonçalves, Ana Alice Maia
Ottino, Jennifer
Leite, Jaqueline Costa
Resende, Lucilene Aparecida
Melo Júnior, Otoni Alves de Oliveira
Silveira, Patricia
Cardoso, Mariana Santos
Fujiwara, Ricardo Toshio
Bueno, Lilian Lacerda
Santos, Renato Lima
Carvalho, Tatiane Furtado de
Garcia, Giani Martins
Paes, Paulo Ricardo de Oliveira
Galdino, Alexsandro Sobreira
Chávez Fumagalli, Miguel Angel
Melo, Marilia Martins
Lemos, Denise da Silveira
Martins Filho, Olindo Assis
Dutra, Walderez Ornelas
Mosqueira, Vanessa Carla Furtado
Giunchetti, Rodolfo Cordeiro
Keywords: Nanotechnology
Vaccine
Issue Date: 2023
Citation: CABRERA GONZÁLEZ, M. A. et al. Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral leishmaniasis in hamster. Vaccines, v. 11, n. 1, artigo 111, 2023. Disponível em: <https://www.mdpi.com/2076-393X/11/1/111>. Acesso em: 01 ago. 2023.
Abstract: Visceral leishmaniasis (VL) is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/17623
metadata.dc.identifier.doi: https://doi.org/10.3390/vaccines11010111
ISSN: 2076-393X
metadata.dc.rights.license: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_VaccinationFormulationNanoparticles.pdf3,55 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.